These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14504198)

  • 21. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma.
    Noonan-Wheeler FC; Wu W; Roehl KA; Klim A; Haugen J; Suarez BK; Kibel AS
    Prostate; 2006 Jan; 66(1):49-56. PubMed ID: 16114055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men.
    Izmirli M; Arikan B; Bayazit Y; Alptekin D
    Asian Pac J Cancer Prev; 2011; 12(3):731-3. PubMed ID: 21627373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.
    Rennert H; Zeigler-Johnson CM; Addya K; Finley MJ; Walker AH; Spangler E; Leonard DG; Wein A; Malkowicz SB; Rebbeck TR
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):949-57. PubMed ID: 15824169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms of HPC2/ELAC2 and SRD5A2 (5α-Reductase Type II) Genes in Prostate Cancer.
    Izmirli M; Arikan B; Bayazit Y; Alptekin D
    Balkan J Med Genet; 2011 Jun; 14(1):31-6. PubMed ID: 24052700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men.
    Agalliu I; Langeberg WJ; Lampe JW; Salinas CA; Stanford JL
    Prostate; 2006 Feb; 66(2):146-56. PubMed ID: 16173036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer.
    Wu YQ; Chen H; Rubin MA; Wojno KJ; Cooney KA
    Cancer Res; 2001 Dec; 61(24):8651-3. PubMed ID: 11751379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.
    Zheng SL; Sun J; Cheng Y; Li G; Hsu FC; Zhu Y; Chang BL; Liu W; Kim JW; Turner AR; Gielzak M; Yan G; Isaacs SD; Wiley KE; Sauvageot J; Chen HS; Gurganus R; Mangold LA; Trock BJ; Gronberg H; Duggan D; Carpten JD; Partin AW; Walsh PC; Xu J; Isaacs WB
    J Natl Cancer Inst; 2007 Oct; 99(20):1525-33. PubMed ID: 17925536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes.
    Langeberg WJ; Kwon EM; Koopmeiners JS; Ostrander EA; Stanford JL
    Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):258-64. PubMed ID: 20056646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men.
    Beuten J; Gelfond JA; Franke JL; Shook S; Johnson-Pais TL; Thompson IM; Leach RJ
    Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):588-99. PubMed ID: 20086112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
    Paris PL; Kupelian PA; Hall JM; Williams TL; Levin H; Klein EA; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):901-5. PubMed ID: 10548319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer.
    Holick CN; Stanford JL; Kwon EM; Ostrander EA; Nejentsev S; Peters U
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1990-9. PubMed ID: 17932346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
    Neslund-Dudas C; Bock CH; Monaghan K; Nock NL; Yang JJ; Rundle A; Tang D; Rybicki BA
    Prostate; 2007 Nov; 67(15):1654-63. PubMed ID: 17823934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of the Ser217Leu Variant of the ELAC2 Gene and Its Association with Prostate Cancer in Population of the Littoral Region of Cameroon.
    Djomkam ALZ; Beyeme Sala T; Baari Memba C; Njimoh DL
    Prostate Cancer; 2019; 2019():5974928. PubMed ID: 31321101
    [No Abstract]   [Full Text] [Related]  

  • 34. ELAC2 and prostate cancer risk in Afro-Caribbeans of Tobago.
    Shea PR; Ferrell RE; Patrick AL; Kuller LH; Bunker CH
    Hum Genet; 2002 Oct; 111(4-5):398-400. PubMed ID: 12384782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer.
    Ewart-Toland A; Chan JM; Yuan J; Balmain A; Ma J
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):759-64. PubMed ID: 15159307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Replication of prostate cancer risk loci in a Japanese case-control association study.
    Yamada H; Penney KL; Takahashi H; Katoh T; Yamano Y; Yamakado M; Kimura T; Kuruma H; Kamata Y; Egawa S; Freedman ML
    J Natl Cancer Inst; 2009 Oct; 101(19):1330-6. PubMed ID: 19726753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.
    Alvarez-Cubero MJ; Pascual-Geler M; Martinez-Gonzalez LJ; Expósito Ruiz M; Saiz M; Cozar JM; Lorente JA
    Urol Oncol; 2016 Oct; 34(10):431.e1-8. PubMed ID: 27318894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness.
    Casey G; Neville PJ; Liu X; Plummer SJ; Cicek MS; Krumroy LM; Curran AP; McGreevy MR; Catalona WJ; Klein EA; Witte JS
    Hum Mol Genet; 2006 Mar; 15(5):735-41. PubMed ID: 16434482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor.
    Ingles SA; Ross RK; Yu MC; Irvine RA; La Pera G; Haile RW; Coetzee GA
    J Natl Cancer Inst; 1997 Jan; 89(2):166-70. PubMed ID: 8998186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.
    He Y; Gu J; Strom S; Logothetis CJ; Kim J; Wu X
    Clin Cancer Res; 2014 Oct; 20(19):5133-5139. PubMed ID: 25274378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.